Results
During the period January 2014 to December 2017, 11 ultra-high-risk GTN patients with liver or brain metastases received first-line multiple-agent chemotherapy treatment at the Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, China, including one patient with concomitant liver and brain metastases. Liver and brain metastases accounted for 1.3% (4/298) and 2.7% (8/298) of 298 GTN patients, respectively, including one patient with concomitant liver and brain metastases.